𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis

✍ Scribed by Sweiss, Nadera J. ;Welsch, Michael Jude ;Curran, James J. ;Ellman, Michael H.

Book ID
101653117
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
97 KB
Volume
53
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Direct evidence for rapid and selective
Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor
✍ Jeffrey M. Farma; Markus Puhlmann; Perry A. Soriano; Derrick Cox; Giulio F. Paci 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 869 KB

## Abstract Tumor necrosis factor (TNF) causes regression of advanced cancers when used in isolation perfusion with melphalan; evidence suggests these effects are mediated __via__ selective yet uncharacterized actions on tumor neovasculature. A novel derivative, colloidal gold bound TNF (cAu‐TNF) h

Listeria monocytogenes infection as a co
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α–neutralizing agents
✍ Nancy R. Slifman; Sharon K. Gershon; Jong-Hoon Lee; Evelyne T. Edwards; M. Miles 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## Abstract ## Objective Tumor necrosis factor α (TNFα) has been implicated in the pathogenesis of certain inflammatory diseases. Two TNFα‐neutralizing agents are licensed in the US. Infliximab is licensed for the treatment of Crohn's disease (CD) and, when used with methotrexate, for the treatmen

A tumor necrosis factor receptor loop pe
A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti–tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis
✍ Hiroaki Saito; Takefumi Kojima; Mariko Takahashi; William C. Horne; Roland Baron 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 829 KB

## Abstract ## Objective The cyclic peptide WP9QY (YCWSQYLCY) was designed to mimic the most critical tumor necrosis factor α (TNFα) recognition loop on TNF receptor I, and it prevents interactions of TNFα with its receptor. We undertook this study to compare the effects of the WP9QY peptide on co

Recombinant human soluble tumor necrosis
Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation
✍ Alessandro Busca; Franco Locatelli; Filippo Marmont; Cristina Ceretto; Michele F 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 2 views

## Abstract Etanercept is a recombinant human soluble tumor necrosis factor (TNF‐α) receptor fusion protein that inhibits TNF‐α, a major mediator in the pathogenesis of graft‐versus‐host disease (GVHD). The purpose of our study was to evaluate the safety and efficacy of etanercept therapy in 21 pat